1' s innovative drug Rasta Capsule (trade name: Ai Rui Zhuo) was approved for listing through the priority review and approval procedures. This drug is used to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, and it has not been listed in other countries at present. The unique innovation mechanism in the world is the first in China to benefit patients.
The number of patients with chronic kidney disease in China has exceeded 65.438+0.2 billion. Renal anemia is one of the common complications of CKD, and the incidence of dialysis is 98.2%. Poor control of renal anemia increases the risk of cardiovascular events and death of dialysis patients, which not only affects their physical and mental health and social function, but also brings heavy disease burden to families and society.
Chen Xiangmei, an academician of China Academy of Engineering and director of the Institute of Nephrology of the People's Liberation Army, pointed out that there has been no innovative drug with new mechanism in the field of renal anemia for a long time. Rosa is expected to help CKD patients in China to improve the standard rate of anemia treatment and significantly improve their quality of life. Rosa and Chen Nan, the chief clinical researcher of China Phase III and Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, said, "Thanks to the improvement of the medical innovation environment in China, China researchers have a better opportunity to be on the same stage with their international counterparts, with a new global mechanism of action and the incubation initiated by China, which promotes the global synchronous research and development of the original drugs and demonstrates the scientific research strength of China's medical and health industry."